US approves updated Pfizer, Moderna shots targeting Omicron / Photo: Joseph Prezioso - AFP/File
-
Sweeping Vietnam internet law comes into force
-
Pope kicks off Christmas under shadow of war
-
Catholics hold muted Christmas mass in Indonesia's Sharia stronghold
-
Japan's top diplomat in China to address 'challenges'
-
Thousands attend Christmas charity dinner in Buenos Aires
-
Demand for Japanese content booms post 'Shogun'
-
As India's Bollywood shifts, stars and snappers click
-
Mystery drones won't interfere with Santa's work: US tracker
-
Djokovic eyes more Slam glory as Swiatek returns under doping cloud
-
Australia's in-form Head confirmed fit for Boxing Day Test
-
Brazilian midfielder Oscar returns to Sao Paulo
-
'Wemby' and 'Ant-Man' to make NBA Christmas debuts
-
US agency focused on foreign disinformation shuts down
-
On Christmas Eve, Pope Francis launches holy Jubilee year
-
'Like a dream': AFP photographer's return to Syria
-
Chiefs seek top seed in holiday test for playoff-bound NFL teams
-
Panamanians protest 'public enemy' Trump's canal threat
-
Cyclone death toll in Mayotte rises to 39
-
Ecuador vice president says Noboa seeking her 'banishment'
-
Leicester boss Van Nistelrooy aware of 'bigger picture' as Liverpool await
-
Syria authorities say armed groups have agreed to disband
-
Maresca expects Man City to be in title hunt as he downplays Chelsea's chancs
-
Man Utd boss Amorim vows to stay on course despite Rashford row
-
South Africa opt for all-pace attack against Pakistan
-
Guardiola adamant Man City slump not all about Haaland
-
Global stocks mostly higher in thin pre-Christmas trade
-
Bethlehem marks sombre Christmas under shadow of war
-
NASA probe makes closest ever pass by the Sun
-
11 killed in blast at Turkey explosives plant
-
Indonesia considers parole for ex-terror chiefs: official
-
Global stocks mostly rise in thin pre-Christmas trade
-
Postecoglou says Spurs 'need to reinforce' in transfer window
-
Le Pen says days of new French govt numbered
-
Global stocks mostly rise after US tech rally
-
Villa boss Emery set for 'very difficult' clash with Newcastle
-
Investors swoop in to save German flying taxi startup
-
How Finnish youth learn to spot disinformation
-
South Korean opposition postpones decision to impeach acting president
-
12 killed in blast at Turkey explosives plant
-
Panama leaders past and present reject Trump's threat of Canal takeover
-
Hong Kong police issue fresh bounties for activists overseas
-
Saving the mysterious African manatee at Cameroon hotspot
-
India consider second spinner for Boxing Day Test
-
London wall illuminates Covid's enduring pain at Christmas
-
Poyet appointed manager at South Korea's Jeonbuk
-
South Korea's opposition vows to impeach acting president
-
The tsunami detection buoys safeguarding lives in Thailand
-
Teen Konstas to open for Australia in Boxing Day India Test
-
Asian stocks mostly up after US tech rally
-
US panel could not reach consensus on US-Japan steel deal: Nippon
NYSE - LSE
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
T.Ward--AMWN
